Citicoline sodium

Quick links to important sections

Citicoline sodium

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citicoline sodium

Property Description
Active ingredient Citicoline (CDP-choline)
Form Injection, Tablet, Oral Solution
Pharmacological class Nootropic and Neuroprotective Agent
Common use Supporting cognitive function
Origin Endogenous Metabolite (naturally occurring)

Citicoline sodium is a foundational pharmaceutical compound used primarily as a nootropic agent and neuroprotective compound that supports the health and function of the central nervous system. This substance is the stabilized sodium salt form of Citicoline, which is chemically known as Cytidine 5'-diphosphocholine or CDP-choline. As an essential endogenous metabolite, Citicoline is naturally present in the human body and is classified within the wider group of Central Nervous System Agents for its role in cellular maintenance and signaling.


What Type of Compound is Citicoline Sodium?

Citicoline sodium is classified as an endogenous metabolite and a neuroprotective compound, acting as a precursor to vital brain components. The core Citicoline molecule is virtually identical to the intermediate compound required by the body's natural cellular processes. Its classification as a nootropic with neuroprotective properties is clinically recognized. It is formally categorized among other psychostimulants and nootropics. The compound functions as a single active ingredient product and is designed to efficiently supply the necessary building blocks for healthy neuronal function.

Composition and Available Forms of Citicoline

The medication's active component is Citicoline sodium, which is highly water-soluble due to its salt form. The compound is provided in several dosage forms, often utilizing an aqueous solution base for its liquid preparations, which include both oral solution and specialized injection solutions. It is also manufactured in solid form as film-coated tablets. These forms allow for delivery via either the oral route or the parenteral (intravenous or intramuscular) route, often targeting older adult patient groups.


Citicoline's General Purpose in Brain Health

The general purpose of Citicoline is to provide fundamental structural support and neuroprotection for brain tissue. This compound acts as a crucial precursor in the synthesis of phosphatidylcholine, which is the main structural component of all neuronal cell membranes. By supplying the necessary material, Citicoline helps to maintain the integrity and stability of nerve cells, generally supporting overall cognitive function and the brain’s energy processes. Citicoline supports cell membrane integrity and aids in supporting neuronal recovery. This compound plays an important role in helping the brain repair and protect its cells, typically relevant in scenarios requiring support for age-related cognitive vitality.

What side effects are possible with Citicoline sodium?

Possible Side Effects and Safety Information

Citicoline sodium (also known as CDP-choline) is generally considered safe and well-tolerated when used appropriately, particularly in short-term studies. However, as with any compound, it may cause side effects in some individuals. Most reported adverse effects are mild and transient.


Common and Less Common Adverse Effects

The most frequently reported side effects are related to the gastrointestinal tract and the central nervous system. These effects are typically not severe and often resolve without intervention.

System Common Side Effects Less Common Side Effects
Gastrointestinal Nausea, Vomiting, Diarrhea, Stomach upset Headache, Dizziness
Cardiovascular Hypotension (low blood pressure) Bradycardia (slow heart rate), Tachycardia (fast heart rate)
Other Insomnia (sleeplessness), Restlessness, Transient changes in liver enzyme levels Allergic reactions (rare)

Contraindications and Precautions

Citicoline should be used with caution in patients with a history of hemorrhagic stroke (bleeding in the brain), especially in the acute phase, as high doses may theoretically worsen cerebral hemorrhage. While evidence is not conclusive, professional medical guidance is necessary in such cases.

There is insufficient reliable information regarding the safety of citicoline during pregnancy and breast-feeding. Therefore, it is generally advised to avoid its use during these periods unless specifically recommended by a healthcare professional after a careful risk-benefit analysis.

Patients taking Levodopa should be monitored, as citicoline may enhance the effects of this medication.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Citicoline sodium overdose is primarily defined by its documented low toxicity, rather than a severe, distinct clinical syndrome. This information is derived from government-authorized prescribing documents.

Overdose Feature Official Regulatory Statement
Documented Manifestations The substance exhibits a very low toxicity profile in humans. Regulatory data confirms that the appearance of intoxication is unlikely due to this negligible inherent toxicity.
Toxicity Threshold Regulatory assessments note the compound has been observed to be safe at doses up to 2 g/day in clinical settings. Furthermore, no deaths occurred even at the maximum possible oral dose, which establishes a minimal acute toxicity threshold.
Antidote No specific antidote for Citicoline overdose is known or documented in the official labeling.

Management and Emergency Response

Official documentation defines the required actions for accidental overdose situations.

Required Action: In the event of an overdose, the mandated procedure is to carry out symptomatic therapy. Management is universally described as supportive.

When to seek medical help: The official labeling does not contain specific, drug-related instructions for contacting emergency services, as the regulatory assessment focuses on the substance's low intrinsic risk. Immediate medical attention must be sought for any severe or life-threatening symptoms that may occur, as is standard for any unexpected serious physiological change.

This profile directs all care toward supportive measures, reflecting the official classification of the overdose scenario as having minimal acute toxicity concern.

Therapeutic Uses of Citicoline sodium

Citicoline sodium may be part of symptomatic management, applied across domains where additional symptomatic support is needed. It is commonly used to address symptom clusters that may become intense or disruptive and interfere with a patient's daily functioning. Its use is relevant in therapeutic areas involving heightened symptom expression.


The medication is relevant for easing symptoms related to cognitive decline, neurological damage (such as post-stroke motor impairment), and certain visual conditions linked to nerve deterioration. It is applied in clinical settings that involve acute or unstable symptom patterns, providing supportive relief when symptoms interfere with routine activities.

“It is commonly used across conditions presenting with acute episodes and contributes to improved comfort during symptomatic periods.”

Quick Fact: Symptomatic Support for Cognitive Strain

Quick Fact: Symptomatic Support for Cognitive Strain – Citicoline sodium is relevant for easing symptoms that interfere with daily comfort, such as poor memory and difficulty concentrating, which may assist with maintaining functional stability during symptomatic periods.

Regulatory References

  1. Health Canada Product Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Citicoline Sodium

Official regulatory documents define specific patient populations for whom Citicoline sodium is either allowed, restricted, or contraindicated.

Populations with Absolute Non-Eligibility

Use of this medicine is contraindicated and strictly prohibited in patients who have a known hypersensitivity or allergy to citicoline or any of the product’s components. It is also contraindicated in patients diagnosed with hypertonia of the parasympathetic nervous system.


Age-Related and Vulnerable Population Restrictions

  • Adults and Older Adults: Use is established in the adult population. For older adults, official labeling notes that a routine dose adjustment is typically not required.
  • Children: Use in children is generally not recommended because regulatory data regarding its safety and efficacy in the pediatric population is not established.
  • Pregnancy and Lactation: Use during pregnancy and breastfeeding is conditional. It should only be considered if the potential benefits are explicitly judged to outweigh the potential risks, as regulatory safety evidence for these groups is insufficient.

Conditional Use Restrictions

Special caution is mandated for patients with persistent intracranial hemorrhage. For these individuals, the medicine, particularly the injection form, must be administered under a specific slow administration restriction to manage potential effects on cerebral blood flow. Furthermore, caution is advised for patients with a known intolerance to specific sugars if the formulation contains such excipients.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Citicoline sodium

This section summarizes the officially documented interaction patterns for Citicoline sodium based strictly on government regulatory documents, such as the Summary of Product Characteristics (SmPC) and official prescribing information.

Interaction Scope

Category Official Regulatory Statement
Medicinal products with documented interactions Meclofenoxate (Clophenoxate / Centrophenoxine), Levodopa (L-dihydroxyphenylalanine)
Mechanistic basis of interactions Pharmacodynamic potentiation (enhancement of effect)
Timing-based interaction rules Co-administration is formally prohibited (must not be used in conjunction or synchronously) with Meclofenoxate.
Interaction-related restrictions Alcohol consumption is restricted (should not be consumed while the preparation is in use).
Population-specific interaction notes None explicitly documented for drug–drug or drug–substance interactions.

Interaction Classifications (High-Level)

Category Official Regulatory Classification/Basis
Interaction severity classification Contraindication (with Meclofenoxate), Clinically significant potentiation (with Levodopa)
Regulatory basis Product information derived from Summary of Product Characteristics (SmPC) and equivalent national regulatory product labels.

Resulting Interaction Structure

Official interaction statements:

  • The co-administration of Citicoline sodium with medicinal products containing Meclofenoxate (Clophenoxate/Centrophenoxine) is a contraindication and must not be administered.
  • Citicoline is officially documented to potentiate (enhance) the effects of Levodopa and L-dihydroxyphenylalanine.
  • Regulatory product information includes a restriction that alcohol should not be consumed during the preparation’s use.

The regulatory interaction profile is defined by a formal, absolute prohibition against co-administration with Meclofenoxate. Additionally, the label documents a clear pharmacodynamic potentiation effect with dopaminergic agents such as Levodopa, resulting in enhanced clinical outcomes. These official label statements establish the mandatory co-administration limits for Citicoline sodium as described in the official product labeling.

Mechanism of Action

Phospholipid Precursor and Membrane Repair

Citicoline sodium (CDP-choline) is a key endogenous intermediate that disassociates into choline and cytidine upon administration. The subsequent re-synthesis into CDP-choline within the central nervous system provides an essential substrate for the Kennedy pathway. This pathway is the primary route for the biosynthesis of phosphatidylcholine, a foundational structural component of neuronal cell membranes. This mechanism facilitates the maintenance and repair of membrane integrity, which is necessary for stable cellular signaling and function.


Neurotransmitter Modulation and Cellular Regulation

The released choline moiety serves as an immediate donor for the production of the neurotransmitter acetylcholine. This contributes to the modulation of central nervous system signaling pathways. Additionally, Citicoline influences the activity and levels of other central transmitters, including dopamine and norepinephrine. Through its regulatory effect on phospholipase enzymes, Citicoline limits the accumulation of free fatty acids. This action, along with the stimulation of glutathione synthesis, influences cellular responses to oxidative stress and membrane damage.

Dosage and Administration Information

Citicoline sodium is administered in clinical practice through multiple routes to support continuity of use. The medicine is available in both oral dosage forms, such as film-coated tablets, capsules, and solutions/syrups, and in parenteral forms for intravenous (IV) or intramuscular (IM) injection.

The daily dose for adult use is defined within a range of 500 mg to 2000 mg. This regimen is typically administered once daily or in divided doses, with the total duration being individualized based on the patient’s condition severity. For older adult patients, dose adjustment is generally not required. Clinical experience is limited for use in pediatric populations.

Specific procedural steps are followed when administering the medicine parenterally. Intravenous injection is delivered very slowly, typically over a period of three to five minutes, to comply with administration constraints. The use of an oral solution or syrup is provided as an option for patients who cannot swallow solid forms. Furthermore, a procedural restriction exists against the synchronous administration of Citicoline sodium with medicinal products containing meclofenoxate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Citicoline Sodium


Research Evidence for Acute Neurological Support (Stroke)

This section summarizes the structure of evidence from Randomized Controlled Trials (RCTs) of varying sizes and subsequent Systematic Reviews that investigated Citicoline sodium in patients with acute ischemic stroke, focusing on measures used for functional outcome and neurological deficit.

Studies focused on patient populations who had experienced a stroke within a short time frame. Researchers examined outcomes related to all-cause mortality, as well as standardized scales monitoring daily functioning and activity level in these acute settings.

Across the pooled data from multiple trials, which often used a placebo or standard care comparator, studies reported patterns related to daily functioning and mortality over the short-term follow-up period, often 90 days. Authoritative reviews documented that many of the included trials had a notable risk of bias in their design, and major scientific reviews consistently rated the overall certainty of this evidence as low. Reported outcomes were short-term and based on large populations.

What remains uncertain is the consistency of findings across the different acute ischemic stroke studies, which showed high variability. Long-term effects on functional outcomes and disability are not fully established. Available evidence provides limited insight into how specific subgroups of stroke patients, such as those with different levels of severity, were monitored.


Research Evidence for Cognitive Decline and Memory Support

This section details the research structure for its use in patients with conditions like Mild Cognitive Impairment and Vascular Dementia. It summarizes the types of trials used and the cognitive domains (e.g., attention and memory) and assessment tools that were specifically evaluated.

The evidence base relies on Systematic Reviews and Meta-analyses that have pooled results from smaller Randomized Controlled Trials (RCTs). Researchers examined outcomes related to functional status by monitoring measures of overall cognitive assessment and specific testing of cognitive domains like memory and attention. Study populations primarily consisted of older adults diagnosed with conditions such as Mild Cognitive Impairment (MCI) or Vascular Dementia (VaD).

Studies reported how symptoms evolved in the observed populations, with analyses describing measured changes in specific areas like attention and executive function over moderate-term periods (up to 12 months). These trials commonly compared results against a placebo. However, research highlights that the overall quality of the studies was poor, and there was a frequent, significant risk of bias in the evidence. Findings were mixed and showed variability across different cognitive tests used.

Studies in Healthy Older Adults

Research examined the compound in healthy adults often included due to age-associated memory complaints, utilizing short-term, randomized, placebo-controlled trials. These studies provide insight into short-term changes observed in specific measures like episodic memory and attention control. The results apply only to the populations studied, and follow-up was limited to short-term periods (e.g., 12 weeks).


Evidence Quality and Research Uncertainty

Authoritative systematic reviews frequently described the overall quality of the evidence as low and noted a significant risk of bias across many of the included trials. Findings were mixed, particularly when comparing outcomes across different study designs and patient groups.

Research gaps include the lack of robust data on long-term effects, as follow-up durations were limited in key studies. Additionally, comparative evidence is lacking, and data for certain groups remain insufficient. The results apply only to the populations studied in the specific research contexts.

Frequently Asked Questions (FAQ)

Common questions about Citicoline sodium (FAQ)


Q: Can Citicoline sodium be taken with food?

Official product instructions for the oral forms of Citicoline sodium generally indicate that the medicine may be taken with or without food.


Q: Are there any long-term safety concerns with taking Citicoline sodium?

Clinical studies have examined the compound's safety profile for use over periods up to 90 days or 12 months. However, official documents note that there is insufficient reliable information available to confirm its safety or effectiveness for very long-term use beyond these monitored study durations.


Q: Does Citicoline sodium interact with common pain relievers like ibuprofen?

Official regulatory documents specifically list only certain compounds, such as Meclofenoxate and Levodopa, as having documented interactions with Citicoline sodium. Other common pain relievers, such as NSAIDs, are not included in the official regulatory documents listing known interactions.


Q: What does 'sodium' mean in the name Citicoline sodium?

Citicoline sodium is the stabilized sodium salt form of the active molecule, which is chemically known as CDP-choline. This salt form makes the compound highly water-soluble and stable, allowing it to be formulated into different dosage types, such as solutions and tablets.


Q: Can Citicoline sodium cause stomach upset?

Yes, some of the most frequently reported adverse effects relate to the gastrointestinal system. Reported side effects may include symptoms like nausea, vomiting, diarrhea, and general stomach upset (epigastric distress), which are typically transient.


Q: Does taking Citicoline sodium affect sleep?

Official product labeling lists Insomnia (difficulty sleeping or sleeplessness) as a possible adverse effect. Other related nervous system effects like restlessness are also documented in official sources.


Q: Is it common to feel a headache when starting Citicoline sodium?

Headache is listed as a reported adverse effect in the official documents. However, official sources do not specify whether this side effect is more likely to occur only when first starting the treatment, or if it can occur at any point.


Q: Is Citicoline sodium available without a prescription?

The regulatory status of Citicoline sodium varies by region. It is generally classified as a psychostimulant/nootropic agent by major health organizations. In some regions, official labeling classifies it as a prescription medicine. Regulatory status varies by country and jurisdiction.


Q: Can teenagers or young adults use Citicoline sodium?

Use is established for the adult and older adult populations. However, official documents state that regulatory data on safety and efficacy for the pediatric population (children) is not established. Data on safety and efficacy for adolescents and younger adults is generally not established in official regulatory documents.


Q: Does Citicoline sodium interact with thyroid medication?

Official regulatory documents only explicitly name Meclofenoxate and Levodopa as known interactions. Other common endocrine medications, such as thyroid drugs, are not explicitly mentioned in the official regulatory interaction summary.


Q: Is Citicoline sodium ever given by injection?

Yes, official documents confirm that the medicine is manufactured and approved for administration not only in oral forms (tablets, solutions) but also in parenteral forms for both intravenous (IV) and intramuscular (IM) injection.


Q: What is the recommended storage condition for Citicoline sodium products?

Regulatory documents state that products must be stored at temperatures not exceeding 30 C and should be protected from light. Refrigeration is not generally required unless the specific product label specifies otherwise.


Q: Are there specific groups of people who should be cautious about using Citicoline sodium?

Yes, special caution is generally advised for patients with a history of persistent intracranial hemorrhage (bleeding in the brain). Use is strictly contraindicated in cases of known hypersensitivity (allergy) to the compound or hypertonia of the parasympathetic nervous system.


Q: What are the most commonly reported but non-serious side effects?

The most frequently reported adverse effects are generally considered mild. They often relate to the gastrointestinal tract (such as nausea, vomiting, or diarrhea) and the central nervous system (such as headache, dizziness, or insomnia).


Q: Is it okay to take Citicoline sodium if I have high blood pressure?

While high blood pressure (hyptertension) is not listed as a contraindication, official labeling notes that hypotension (low blood pressure) is a possible side effect, and caution may be advised for certain individuals.


Q: Is Citicoline sodium a vitamin or a supplement?

Citicoline is structurally an endogenous metabolite and is classified by the World Health Organization (WHO) as an other psychostimulant and nootropic agent. It is not generally classified as a vitamin in official regulatory systems.


Q: Does Citicoline sodium affect liver function?

Official product labeling notes that a possible reported adverse effect is transient changes in liver enzyme levels. Official documents report that these changes are generally considered transient.


Q: Is there any research on Citicoline sodium and concussion recovery?

Authoritative medical literature indicates that research has examined the compound in contexts related to outcomes in patients following different types of head injury.


Q: Why do some people take Citicoline sodium even if they don't have a specific condition?

Research has included studies examining the compound in healthy adults and older individuals with age-associated memory complaints. This research indicates that its use is not limited exclusively to people with a formally diagnosed condition.


Q: What does the research show about Citicoline sodium for fatigue?

Official product labeling includes fatigue as one of the possible undesirable effects reported in some instances. It is listed as a recognized, though not necessarily common, reaction.


Q: Are there any documented cases of addiction to Citicoline sodium?

Authoritative scientific reviews have examined the compound's characteristics. These reviews have found the compound to be generally well tolerated and have not indicated a liability for addiction or dependency.


Q: Are there any known food restrictions while using Citicoline sodium?

Official regulatory product information explicitly includes a restriction that alcohol should not be consumed while the preparation is in use. No specific food restrictions are typically listed in the official documents.


Q: Can Citicoline sodium cause anxiety or nervousness?

Official product labeling lists restlessness and insomnia (sleeplessness) as reported nervous system side effects. The terms anxiety or nervousness are not typically listed among the specific undesirable effects in the official documents.


Q: What is the evidence theme for Citicoline sodium use in eye health?

Research evidence themes include its use in the field of ophthalmological neurodegenerative diseases. This research examines the compound's mechanisms in supporting nerve cell membranes, particularly in conditions such as glaucoma and diabetic retinopathy.


Q: Is Citicoline sodium a naturally occurring substance in the body?

Yes, the compound is chemically the same as CDP-choline, an essential endogenous metabolite. This substance is naturally synthesized and present in living cells, where it serves as a necessary intermediate in the body's cell membrane synthesis processes.


Q: How does the body eliminate Citicoline sodium?

After being absorbed and utilized, the body eliminates the compound's metabolites through two main routes. The majority of elimination occurs via the respiratory route as carbon dioxide ( CO2) and the remainder is eliminated via urinary excretion.

How should Citicoline sodium be stored and disposed of?

Storage and Disposal of Citicoline Sodium

Official regulatory documents define specific conditions to maintain the stability and safety of Citicoline sodium. The product must be stored at temperatures not exceeding 30 C and, for certain tablet formulations, protected from light.

Handling and Stability

The solution for injection is provided for single use only. Once the ampoule is opened, it must be administered immediately, and any unused content must be discarded to preserve sterility and stability.

Safety and Disposal Rules

All forms of the medicine must be stored out of the sight and reach of children. The disposal of any expired or unused medicinal product and its waste material is mandatory and must be executed in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citicoline sodium found in:

A-Z Index: